Literature DB >> 16717394

A case of hepatitis C-associated osteosclerosis in an elderly Japanese man.

Tokuji Tanaka1, Shogo Oki, Seiji Muro, Kiyoshi Tanaka, Jun Hashimoto.   

Abstract

Hepatitis C-Associated Osteosclerosis (HCAO) is characterized by a marked increase in bone mass with deep bone pain. Since 1992, eleven cases of HCAO have been reported. This report describes an elderly Japanese man with HCAO, whose clinical course we followed for 3 years. A 68-year-old man developed pain in both pretibial regions in June 2000, and he had frequent episodic loss of muscular strength in his hands. He had recieved blood transfusion for a bleeding ulcer 43 years before and was seropositive for hepatitis C virus. His serum alkaline phosphatase (ALP) level was markedly increased, while his serum calcium was slightly decreased and serum phosphate was normal. Skeletal radiographs of the lower extremities showed a progressive increase in skeletal density, but did not show any apparent deformity. Administration of nonsteroidal anti-inflammatory drugs led to a reduction in bone pain. Treatment with vitamin D3 and calcium decreased the number of episodes of sudden muscular weakness and maintained serum calcium within the normal range. Three years after the onset of the disease, bone mineral density of his lumbar vertebrae and left hip rose from 0.963 g/cm2 to 1.096 g/cm2, and from 0.938 g/cm2 to 1.383 g/cm2, respectively. His serum ALP level decreased from 2889 to 277 IU/L (normal range: 104-338) and serum calcium normalized. These findings were accompanied by a decrease in bone pain. This case and previous reports suggest that the skeletal tissue of this disease appears to be of good quality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16717394     DOI: 10.1507/endocrj.k04-131

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  A case of hepatitis C-associated osteosclerosis that was improved with the combination therapy of peginterferon alfa-2b and ribavirin.

Authors:  Satoshi Shakado; Yuko Akehi; Kaoru Yotsumoto; Atsushi Fukunaga; Shizuka Kuno; Takashi Tanaka; Kunitoshi Sakurai; Hideyuki Iwashita; Shuichi Ueda; Genryu Hirano; Keiji Yokoyama; Daisuke Morihara; Shinya Nishizawa; Masaharu Sakamoto; Akira Anan; Yasuaki Takeyama; Makoto Irie; Kaoru Iwata; Tetsuro Sohda; Shotaro Sakisaka
Journal:  Clin J Gastroenterol       Date:  2011-06-10

2.  Vitamin D status and viral response to therapy in hepatitis C infected children.

Authors:  Azza A Eltayeb; Madleen Adel A Abdou; Amal M Abdel-aal; Mostafa H Othman
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

3.  An uncommon cause of acquired osteosclerosis in adults: hepatitis C-associated osteosclerosis.

Authors:  Narendranath Epperla; Fergus E McKiernan
Journal:  Skeletal Radiol       Date:  2014-04-10       Impact factor: 2.199

4.  Hepatitis C-Associated Osteosclerosis: Improvement After Treatment with Sofosbuvir, Daclatasvir, and Ibandronate: Case Report and Literature Review.

Authors:  Maria Carolina de Camargo Vieira; Wagner Rodrigo Brida Gonçalves; Ricardo Ayello Guerra; Fabiana Siroma Callegaro; Marise Lazaretti-Castro; Sergio Setsuo Maeda
Journal:  Calcif Tissue Int       Date:  2021-02-22       Impact factor: 4.333

Review 5.  Current treatment of hepatitis C-associated rheumatic diseases.

Authors:  Clodoveo Ferri; Marco Sebastiani; Alessandro Antonelli; Michele Colaci; A Manfredi; Dilia Giuggioli
Journal:  Arthritis Res Ther       Date:  2012-06-25       Impact factor: 5.156

Review 6.  Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management.

Authors:  Celia L Gregson; Sarah A Hardcastle; Cyrus Cooper; Jonathan H Tobias
Journal:  Rheumatology (Oxford)       Date:  2013-02-27       Impact factor: 7.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.